Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis through Activating AMPK/SIRT1 Pathway

Mengyue Yang,1,2 Hang Lv,1,2 Qi Liu,1,2 Lu Zhang,3 Ruoxi Zhang,1,2 Xingtao Huang,1,2 Xuedong Wang,1,2 Baihe Han,1,2 Shenglong Hou,1,2 Dandan Liu,1,2 Gang Wang,1,2 Jingbo Hou1,2 and Bo Yu1,2

1The Key Laboratory of Myocardial Ischemia Organization, Chinese Ministry of Education, Harbin, Heilongjiang 1500086, China
2Department of Cardiology Organization, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 1500086, China
3Department of Cardiology, The Affiliated Cardiovascular Hospital of Xiamen University, Xiamen, Fujian 316006, China

Correspondence should be addressed to Jingbo Hou; jingbohou@163.com

Received 18 December 2019; Accepted 20 May 2020; Published 15 July 2020

Academic Editor: Gianluca Carnevale

Copyright © 2020 Mengyue Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cholesterol crystal- (CC-) induced endothelial cell inflammation and pyroptosis play an important role in the development of cardiovascular diseases, especially in atherosclerosis (AS). Increasing evidence suggests that cholesterol crystals are known to be a pivotal pathological marker of atherosclerotic plaque vulnerability. As a classical nonspecific anti-inflammatory drug, colchicine has been widely used in the treatment of acute gout. However, whether colchicine could alleviate CC-induced endothelial cell injury and the related mechanisms remains to be addressed. In this study, the protective effect of colchicine on human umbilical vein endothelial cells (HUVECs) was confirmed. Our results revealed that after cotreatment with colchicine and cholesterol crystals in endothelial cells, the uptake of cholesterol crystals was significantly decreased, the cell viability was obviously increased, and the release of lactate dehydrogenase (LDH) and the number of pyroptotic cells decreased significantly; then, the expression of NLRP3 in inflammasome-related proteins and various inflammatory factors was also visibly suppressed; moreover, as a potent activator of NLRP3 inflammasome, the intracellular ROS level was clearly reduced, while mitochondrial membrane potential improved significantly. In addition, the expression levels of AMP-dependent kinase (AMPK) pathway-related proteins as well as various antioxidant enzymes were elevated notably in varying degrees. However, the above effects of colchicine were completely offset by the treatment of siRNA targeting AMPKα and Sirtuin1 (SIRT1). Therefore, we conclude that colchicine plays a crucial role in alleviating the intracellular inflammatory response and NLRP3 inflammation activation, attenuating the levels of cellular oxidative stress and pyroptosis in endothelial cells via regulating AMPK/SIRT1 signaling, which may be a concrete mechanism for the secondary prevention of cardiovascular diseases.

1. Introduction

Coronary heart disease (CHD) is the most fatal disease in the world, and acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality. Accordingly, vulnerable plaque is the potential culprit of ACS [1]. Pathological studies have shown that the more CC content in atherosclerotic plaque, the faster the plaque progresses and the more prone to rupture or erosion leading to unstable cardiovascular events [2, 3]. Therefore, CC is a pivotal pathological marker of plaque vulnerability.

Extensive studies have found that CC appeared in the initiation of atherosclerotic plaque and was associated with early inflammatory response [2]. CC could activate NLRP3 inflammasome, induce local inflammation, and promote the formation of large necrotic cores and vulnerable plaque [1]. NLRP3 inflammasome is a macromolecule-polyprotein complex that regulates the production of the IL-1 family and plays an important role in the pathogenesis of AS. It can be activated by a variety of damaging molecules such as ATP, uric acid crystal, cholesterol crystal, and asbestos, triggering an intensively aseptic inflammatory response via
upregulating the expression of multiple proinflammatory cytokines [4]; beyond that, pyroptosis implementing protein
GSDMD is cleaved by activated caspase-1, inducing caspase-
1-dependent pyroptotic cell death [5]. Moreover, studies have
demonstrated that reactive oxygen species (ROS) plays a cru-
cial role in the activation of inflammasome, and pretreatment
with various ROS scavengers represses NLRP3 inflamma-
some activation in response to a series of agonists [6, 7].

Pyroptosis is a newly discovered type of programmed cell
death accompanied by inflammatory response. Recent studies
have reported that inflammation and pyroptosis play an
important role in the progression of cardiovascular diseases,
as such as atherosclerosis, myocardial infarction and ischemia-
reperfusion injury, diabetic cardiomyopathy, and heart failure
[8–11]. Different from apoptosis or necroptosis, pyroptotic
cells are manifested as the formation of a large number of pro-
tein holes on the cell membrane, resulting in the rapid loss of
membrane integrity and the significant weakening of the
ability to regulate the flow of substances, thus leading to the
release of proinflammatory substances and the enlarged sec-
ondary inflammation [12]. Therefore, cell pyroptosis may
play a prominent role in AS-interrelated inflammation, and
targeted regulation of pyroptotic cells in atherosclerotic
lesions may be a new direction for the treatment of AS.

Colchicine is a classic treatment for acute gout attacks.
Recent studies have shown that low-dose colchicine can also
be used for the secondary prevention of cardiovascular dis-
ease due to its powerful anti-inflammatory effect [13]. The
latest clinical study published in the New England Journal of
Medicine also showed that in the assessment of 4745 patients
with recent myocardial infarction, taking low-dose colchicine
daily (0.5 mg) significantly reduced the risk of ischemic car-
diovascular events compared with the placebo group [14].
Related research has indicated that colchicine could inhibit
macrophage phenotypic switch induced by monosodium
urate crystals and alleviate macrophage inflammation via
activating the LKB1-AMPK pathway [15]. Moreover, acti-
vated AMPK could enhance the expression level and deacety-
lation activity of SIRT1 by promoting the production of NAD
+, the SIRT1 activator. Furthermore, the activation of SIRT1
could catalyze the deacetylation of peroxisome proliferator-
activated receptor γ coactivator 1α (PGC-1α), then regulate
the expression of various antioxidant enzymes, subsequently
following the deceleration of the intracellular ROS level and
oxidative stress [16]. However, it is unclear whether colchi-
cine could suppress the activation of NLRP3 inflammasome
and cell pyroptosis induced by CC in the progression of AS,
and direct evidence for AMPK/SIRT1 activation in antago-
nizing inflammasome and pyroptosis is still lacking.

In this study, we discovered that colchicine could upreg-
ulate the expression and activity of various antioxidant
enzymes, inhibit ROS production and NLRP3 inflammasome
activation, and antagonize endothelial cell pyroptosis which
was induced by CC via activating the AMPK-SIRT1 pathway.

2. Materials and Methods

2.1. Cell Culture and Reagent Treatments. Human umbilical
vein endothelial cells (HUVECs) were obtained from Science
Cell Research Laboratories (Carlsbad, CA, USA) and cultured
in Endothelial Cell Medium (ECM, Science Cell Research
Laboratories, Carlsbad, CA, USA) supplemented with 1%
edothelial cell growth factors, 5% FBS, and 1% penicillin/
streptomycin at 37°C in a 5% CO2 humidified atmosphere.
Cholesterol (C3045) and total ROS scavenger N-acetyl-L-cys-
teine (NAC, A7250) were purchased from Sigma-Aldrich;
colchicine (HY-16569) was obtained from MCE. For experi-
ments involving pharmacological reagents, endothelial cells
were pretreated with colchicine (0–100 nM) or NAC (5 mM)
for 2 h and subsequently followed by cholesterol crystals
(0.5 mg/ml) for 10–24 h in the presence of these reagents.

2.2. Preparation of Cholesterol Crystals. 100 mg ultrapure
cholesterol powder (Sigma, Saint Louis, MO) dissolved in
8 ml 95% ethanol was heated to 60°C, filtered through What-
man filter paper while still warm, and left at room tempera-
ture to allow crystallization to proceed. After drying,
relatively large cholesterol crystals were developed and
ground with a grinding bowl to make the crystal size within
1–10 μm. The collected crystals were sterilized by autoclaving
and ultraviolet light, then stored at −20°C for reserve. Choles-
terol crystals were used at a final concentration of 0.5 mg/ml
if not otherwise specified.

2.3. Cell Viability Assay. A CCK8 assay was performed to
evaluate cell viability of HUVECs following the manufac-
turer’s instruction (CK04, Dojindo, Kumamoto, Japan). 2 ×
104 endothelial cells were seeded in 96-well plates in com-
plete medium and treated with different concentrations of
colchicine and/or cholesterol crystals for 24 h. Afterwards,
a 10 μl CCK8 reagent was added to each well, and the cells
were incubated for 3 h at 37°C. Absorbance measurements
were taken at 450 nm using a Tecan Infinite M200 microplate
reader (LabX, Austria).

2.4. Hoechst 33342/PI Fluorescent Staining. To assess pyrop-
tosis, cells were double-stained with Hoechst 33342 and pro-
pidium iodide (PI). HUVECs (104 cells/well) were cultured
in a 12-well plate and were pretreated with test drugs or siRNA
for the duration as to be specified in the appropriate section.
After treatments, the cells in each group were washed with
PBS for three times and stained with 2.5 μl Hoechst 33342
and 2.5 μl PI (C1056, Beyotime Institute of Biotechnology,
Shanghai, China) for 30 min at 4°C in the dark. The stained
cells were examined under a fluorescence microscope at
200x magnification (DMI4000B; Leica, Wetzlar, Germany).

2.5. Transmission Electron Microscopy (TEM). The samples
were fixed with 2.5% glutaraldehyde overnight at 4°C and
1% osmium acid for 1.5 h, then rinsed with PBS three times
for 15 min. Endothelial cells were dehydrated with ethanol at
concentration gradients (30%, 50%, 70%, 80%, 90%, 95%,
and 100%) for 15 minutes at a time, then embedded with
a mixture of the embedding agent and acetone overnight
at 70°C. 70-90 nm sections were obtained with Reichert-
Jung Ultracut E Ultramicromette and stained with lead
citrate and uranyl acetate. Finally, the Hitachi H-7650
transmission electron microscope was used for observation
(Hitachi 7650, Japan).
2.12. siRNA Transfection. Small interfering RNAs (siRNAs) sized by RiboBio (Guangzhou, China). HUVECs were seeded according to the manufacturer's instructions. Cytotoxicity was taken (S0053, Beyotime Institute of Biotechnology) according to the manufacturer’s instruction. After 48h incubation with the siRNAs, endothelial cells were exposed to colchicine (10 mM) and cholesterol crystals (0.5 mg/ml) for 24h and then collected for quantitative real-time PCR and Western blotting.

2.13. RNA Isolation and RT-PCR. The TRIZOL reagent (15596018, Invitrogen, CA, USA) was applied to extract total RNA from HUVECs. cDNA was synthesized from 1 μg of total RNA using the iScript gDNA Clear cDNA Synthesis Kit (170-8890, Bio-Rad Laboratories, Redmond, USA). Quantitative RT-PCR was performed using a SsoFast EvaGreen Supermix (172-5260, Bio-Rad Laboratories) on a CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories) following the manufacturer’s protocol. The following optimized conditions were used: 95°C for 30s, 95°C for 5s, and 40 cycles at 60°C for 5s. The levels of mRNA were normalized in relevance to endogenous GAPDH, and the expression of target genes was analyzed by the method of 2-ΔΔCT. The sequence of related genes is shown as follows: AMPKα: forward: 5'-ACCAAGGTCACGCATAC-3', reverse: 5'-TCATCTTCTGATACGCAA-3'; SIRT1: forward: 5'-TAGCCCTTGATAGGAGGA-3', reverse: 5'-ACAGCTTCAGTCAACTTTGT-3'; GSDMD: forward: 5'-GGCGGTGTCATGGGTTGATG-3', reverse: 5'-TCGGGGTGTATTCATCTCTAC-3'; IL-1β: forward: 5'-ATGATGGCTTTATACGATGATG-3', reverse: 5'-TGATGGAGATTCGTA-3'; GCTGGA-3'; IL-6: forward: 5'-ACTCACCTCTTTCAGAA CGAATTG-3', reverse: 5'-GTGACACGGATTTTTCGCA-3'.

2.14. Western Blotting Analysis. Protein extracts from 2×10^6 endothelial cells were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (ISEQ00010, Millipore, Billerica, MA, USA) using a semidry blot apparatus (Bio-Rad Laboratories, Redmond, USA). Subsequently, membranes were blocked with 5% nonfat dried milk (R&D Systems, Minneapolis, MN, USA) in Tris-buffered saline-Tween 20 (TBST) for 1h at room temperature and then probed with specific primary mouse or rabbit antibodies against NLRP3 (Cell Signaling Technology (CST), Danvers, MA, USA, Cat. No.: 15101), ASC (Abcam, Cambridge, MA, USA, Cat. No.: ab70627), procaspase-1 (CST, Cat. No.: 38665), caspase-1 (CST, Cat. No.: 41995), AMPK (CST, Cat. No.: 25328), p-AMPK (CST, Cat. No.: 25355), SIRT1 (CST, Cat. No.: 23105), HO-1 (Abcam, Cat. No.: ab68477), SOD-1 (Abcam, Cat. No.: ab13498), SOD-2...
and concentrations above 100 nM had an obvious toxic effect with various concentrations of colchicine (0-100 nM), (Figure 1(a)). The cell viability was measured after incubation of cholesterol crystals to induce pyroptosis was 0.5 mg/ml [6], using the CCK8 assay, we found that the optimum dose validated mechanism for NLRP3 in the endothelium; the results demonstrated that colchicine significantly inhibited CC-induced mRNA and protein expression of IL-18 and IL-1β (Figures 2(b), 2(c), 2(e), and 2(f)), particularly the mRNA level of GSDMD (Figure 2(d)). Besides, we detected the expression of several inflammatory factors using RT-PCR, and the mRNA levels of IL-6, IL-8, and MCP-1 decreased significantly in the presence of colchicine (Figures 2(g) and 2(i)).

3.3. Colchicine Plays an Antipyroptosis Role by Inhibiting Intracellular Oxidative Stress. ROS generation is a well-established mechanism for NLRP3 inflammasome activation [20]. Therefore, we first detected the changes of the ROS level in the endothelium treated with CC; our results demonstrated that CC treatment dramatically increased ROS levels, and this phenomenon was buffered by colchicine in a concentration-dependent manner (Figure 3(a)). Besides, we also detected a significant improvement in mitochondrial membrane potential, as well as a prominent reduction of the ROS level and the content of GSSG and MDA in the presence of colchicine (Figures 3(b)–3(d)). To further validate the mechanism underlying the suppression of pyroptosis by colchicine, we used a ROS scavenger N-acetyl-cysteine (NAC) and H$_2$O$_2$ as a positive control. Using CCK8, we found that the survival rate of endothelial cells decreased significantly when the H$_2$O$_2$ concentration exceeded 300 μM (Figure 3(e)), and the cell viability was improved distinctly in the presence of NAC and colchicine (Figure 3(f)). The results in (Figures 3(g) and 3(h)) clearly indicated that NAC pretreatment could observably abrogate the release of LDH and the increase of PI-positive cells induced by CC and H$_2$O$_2$. Consistent results were also obtained by detecting the ROS level and the content of GSSG and MDA (Figures 4(a), 4(c), and 4(d)), while mitochondrial membrane potential improved significantly (Figure 4(b)). In addition, NAC also decreased CC and H$_2$O$_2$-induced protein expression levels of inflammasome components, including NLRP3, ASC, and cleaved caspase-1 (Figures 4(e)–4(h)); the gene expression of inflammatory cytokines, such as IL-

(CST, Cat. No.: 13194-4s), IL-18 (CST, Cat. No.: 54943S), IL-1β (CST, Cat. No.: 83186S), eNOS (CST, Cat. No.: 9572S), p-eNOS (CST, Cat. No.: 9571S), and β-actin (TA-09, Zhongshanjinqiao, Inc., Beijing, China; 6600), and the relative intensity was measured and analyzed using ImageJ software.

2.15. Statistical Analysis. All statistical analyses were performed with GraphPad Prism 8.0 software (GraphPad Software, San Diego, CA, USA) and were presented as the mean ± SD. Differences among groups were determined using a one-way ANOVA test. Each experiment was repeated at least three times, and $P$ values < 0.05 were considered statistically significant.

3. Results

3.1. Colchicine Suppresses Cholesterol Crystal-Induced Endothelial Cell Pyroptosis. A previous study has demonstrated that long-term use of low-dose colchicine could improve clinical outcomes in patients with advanced vascular disease by targeting an inflammatory pathway [13]. To examine the possible impact of colchicine on the inflammation of the vascular wall, we firstly explored whether pretreatment with colchicine could inhibit cholesterol crystal-induced endothelial cell pyroptosis. Consistent with a previous report [6], using the CCK8 assay, we found that the optimum dose of cholesterol crystals to induce pyroptosis was 0.5 mg/ml (Figure 1(a)). The cell viability was measured after incubation with various concentrations of colchicine (0-100 nM), and concentrations above 100 nM had an obvious toxic effect (Figure 1(b)). After being exposed to the cotreatment of cholesterol crystals and colchicine, pyroptotic cell death was evaluated by LDH released and Hoechst 33342/PI staining. In addition, cell survival was also detected. CC added to HUVECs significantly increased the release of LDH (Figure 1(e)), and the proportion of PI-positive staining cells was remarkably improved (Figure 1(d)). However, this phenomenon was counteracted by cotreatment with colchicine in a concentration-dependent manner (Figures 1(d)–1(e)). On the other hand, the cell viability decreased by CC was obviously elevated after colchicine intervention (Figure 1(c)). Furthermore, the results of transmission electron microscopy showed that with the increase of colchicine concentration, the cholesterol crystal uptake by endothelial cells decreased gradually, and the number of pyroptotic endothelial cells reduced observably, especially at the concentration of 10 nM (Figure 1(f)).

3.2. Colchicine Alleviates NLRP3 Inflammasome Activation Relevant in Pyroptosis. Pyroptosis is a unique form of programmed cell death accompanied with inflammatory response, which is mediated by inflammasome and is dependent on the activation of caspase-1 [17]. The expression level of NLRP3 was detected with immunofluorescence (Figure 2(a)), and the inflammasome-associated protein levels were measured by Western blot after treatment with CC. As depicted in Figures 2(b) and 2(c), NLRP3 and ASC-1 were remarkably upregulated by CC, as well as the core component cleaved caspase-1. Conversely, colchicine treatment significantly blocked NLRP3 signal activity; the expression levels of NLRP3 and ASC-1 were nearly half compared with the CC group (Figures 2(b) and 2(c)). Moreover, colchicine did not significantly affect procaspase-1 protein expression but attenuated the expression of cleaved caspase-1 (p20 active forms) in response to CC, which was almost twice lower at the concentration of 10 nM (Figures 2(b) and 2(c)). It is well known that NLRP3 inflammasome is a macromolecule polyprotein complex that regulates the production of the IL-1 family [18]; activated caspase-1 subsequently cleaves IL-1β and IL-18 into their bioactive forms, as well as the effector of pyroptosis GSDMD [19]. We next determined the mRNA or protein expression levels of IL-1β, IL-18, and GSDMD in the endothelium; the results demonstrated that colchicine significantly inhibited CC-induced mRNA and protein expression of IL-18 and IL-1β (Figures 2(b), 2(c), 2(e), and 2(f)), particularly the mRNA level of GSDMD (Figure 2(d)). Besides, we detected the expression of several inflammatory factors using RT-PCR, and the mRNA levels of IL-6, IL-8, and MCP-1 decreased significantly in the presence of colchicine (Figures 2(g) and 2(i)).
Figure 1: Continued.
18 and IL-1β, and the critical regulators GSDMD were all blocked by NAC, as well as colchicine at a concentration of 10 nM (Figures 4(i)–4(k)). These results demonstrated that colchicine attenuated CC-induced NLRP3 in flammersome activation and endothelial cell pyroptosis by reducing intracellular ROS overproduction and oxidative stress.

3.4. Colchicine Reverses the Downregulation of Various Antioxidant Enzymes and Promotes the Activation of AMPK-SIRT1 Signaling in Endothelial Cell. The AMPK-SIRT1 pathway plays a crucial role in inhibiting oxidative stress via enhancing the expression of antioxidant enzymes during atherosclerosis [21–23]. Notably, decreased antioxidant enzyme levels were detected in the endothelial cell after CC exposure (Figures 5(a) and 5(d)–5(f)). To further understand the mechanism of the inhibitive role of colchicine in NLRP3 inflammasome activation and HUVEC pyroptosis, we measured the expression levels of AMPK-SIRT1 pathway-related proteins using Western blotting. Compared with HUVECs treated with CC alone, the protein levels of p-AMPK and SIRT1 were all activated by coincubation with 10 nM colchicine (Figures 5(a)–5(c)). Additionally, the presence of colchicine led to a much higher level of antioxidant enzyme expression, including HO-1, SOD-2, and SOD-1, and these effects were particularly obvious at the dose of 10 nM (Figures 5(a) and 5(d)–5(f)). Furthermore, previous experimental studies have proved that antioxidant enzymes can blunt ROS generation to a great extent and sequentially inhibit intracellular oxidation and endothelial cell dysfunction [24]. Therefore, it is plausible to suppose that colchicine may upregulate the expression and activity of various antioxidant enzymes and reduce the production of ROS via activating the AMPK-SIRT1 pathway, thus restraining the activation of NLRP3 inflammasome and endothelial cell pyroptosis induced by CC.

3.5. Silencing of AMPK-SIRT1 Signaling Eliminates the Protective Effect of Colchicine on Endothelial Cells. To further
Figure 2: Continued.
investigate whether colchicine’s protective effect in HUVECs is AMPK-SIRT1 dependent, we carried out siRNA transfection experiment. The gene expression of AMPKα1 and SIRT1 was knocked down in endothelial cells using siRNA, respectively. To verify the silencing efficiency of siRNA, we analyzed the mRNA expression levels of AMPKα1 and SIRT1 in endothelial cells by RT-PCR. The results in Figures 6(a) and 6(b) demonstrated that transfection of si-AMPKα1 and si-SIRT1 significantly decreased the expression level of AMPKα1 and SIRT1 to more than 50% with or without the presence of cholesterol crystals and colchicine, whereas si-control (si-NC) had no obvious effect on HUVECs compared with the control group. Under the condition of CC and colchicine, AMPKα1 and SIRT1 knockdown induced a visible increase in the generation of ROS (Figure 6(c)) and the content of GSSG and MDA (Figures 6(f) and 6(g)), whereas there is an evident decrease of mitochondrial membrane potential (Figure 6(d)). Furthermore, compared with CC and colchicine stimulation, silencing of AMPKα1 and SIRT1 dampened the ability of colchicine to prevent HUVECs from CC-induced pyroptosis, as evidenced by the marked increase in the percentage of PI-positive cells (Figure 6(e)). Silencing of AMPKα1 and SIRT1 significantly suppressed the protein expression of NLRP3, ASC-1, and cleaved caspase-1 (Figures 7(a) and 7(d)–7(f)), along with the inhibition of the gene expression of proinflammatory cytokines (IL-1β, IL-18, IL-6, IL-8, and MCP-1) and GSDMD (Figure 6(h)). Consistent with previous studies [16], AMPKα1 silencing not only reduced the levels of AMPKα1 but also decreased that of SIRT1; transfection of si-SIRT1 only inhibited the expression of SIRT1 but did not significantly affect AMPKα1 protein expression, suggesting that AMPK may be a master upstream regulator of SIRT1 (Figures 6(b) and 7(a)–7(c)). Additionally, silencing of AMPKα1 and SIRT1 also remarkably abrogated the antioxidant enzyme expression even in the presence of colchicine, including HO-1, SOD-2, and SOD-1 (Figures 7(a) and 7(g)–7(i)). These findings confirmed that activating the AMPK-SIRT1 pathway and upregulating multiple antioxidant enzymes are at least partly relevant to the depression effect of colchicine on the inflammatory response and pyroptosis in HUVECs. A schematic summary of the proposed mechanism by which colchicine modulated the function of HUVECs is shown in Figure 8.

4. Discussion

The result presented in the current study demonstrated that colchicine plays a significant protective role in preventing the damage of endothelial cells induced by cholesterol crystals. Colchicine decreased cholesterol crystal-induced ROS generation in HUVECs and then inhibited NLRP3 inflammasome activation and inflammatory response, ultimately ameliorating the pyroptosis of endothelial cells. These effects suggest that colchicine has a promising role in the prevention and treatment of atherosclerosis.

A large number of autopsy evidences revealed that using optical coherence tomography (OCT), scanning electron micrographs, immunofluorescence, pathological staining, and other techniques could detect the dense concentration of cholesterol crystals perforating the fibrous cap and intima or depositing beneath the expandible fibrous cap in the coronary arteries of patients who died of acute coronary syndrome or acute myocardial infarction [2]. Therefore, as a crucial component of atherosclerotic plaque, cholesterol crystals play an important role in vulnerable plaque formation and subsequent cardiovascular adverse events [3]. Previous studies have shown that drugs such as ethanol and statins could dissolve preformed cholesterol crystals in atherosclerotic plaques [25], then provide plaque stabilization. Whereas our results unraveled that low doses of colchicine could inhibit the uptake of cholesterol crystals, while the concentration of colchicine was 0.1 nM, the content and volume of cholesterol crystals decreased significantly; also, the
Figure 3: Colchicine plays an antipyroptosis role by inhibiting intracellular oxidative stress. HUVECs were treated for 10 or 24 h with different doses of colchicine (0–10 nM) in the presence of cholesterol crystal (0.5 mg/ml) or were left untreated (control). (a) Intracellular ROS level was detected using a DCFH-DA probe. (b) JC-1 Staining Kit was used for the detection of mitochondrial membrane potential. (c, d) The indicators of oxidative stress GSSG and MDA were tested by assay kits in endothelial cells. Endothelial cells treated with increasing doses of H₂O₂ (0–400 μM); (e) the cell viability was detected using a CCK8 assay. HUVECs were subjected to H₂O₂ (300 μM), cholesterol crystal (0.5 mg/ml) and colchicine (10 nM), or N-acetyl-cysteine (NAC, 5 mM) for 24 hrs. (f) The cell viability was detected using a CCK8 assay. Pyroptotic cell death was evaluated with (g) LDH release and (h) Hoechst 33342/PI staining. Scale bars = 100 μm. Data was expressed as the mean ± SD of three separate experiments. **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. the control group. "P < 0.05, "P < 0.01, ""P < 0.001, and """"P < 0.0001 vs. the cholesterol crystal group. & P < 0.05, &&&& P < 0.0001 vs. the H₂O₂ group.
Figure 4: Colchicine plays an antipyroptosis role by inhibiting intracellular oxidative stress. HUVECs were subjected to H$_2$O$_2$ (300 $\mu$M), cholesterol crystal (0.5 mg/ml) and colchicine (10 nM), or N-acetyl-cysteine (NAC, 5 mM) for 10 h or 24 h. (a) ROS level was detected using a DCFH-DA probe, and (b) mitochondrial membrane potential was tested by JC-1 (scale bars = 100 $\mu$m). (c, d) The indicators of oxidative stress GSSG and MDA were tested by assay kits. (e) Western blotting was dedicated to examine the protein expression levels of NLRP3, ASC-1, procaspase-1, and caspase-1. (f–h) Quantitative analysis of pyroptosis-associated protein expression. (i, j) Real-time PCR analysis of the mRNA levels of GSDMD and proinflammatory cytokines (IL-18 and IL-1$\beta$). Data was expressed as the mean ± SD of three separate experiments. *$P$ < 0.01, **$P$ < 0.001, and ***$P$ < 0.0001 vs. the control group. &$P$ < 0.05, &&$P$ < 0.01, &&&$P$ < 0.001, and &&&&$P$ < 0.0001 vs. the H$_2$O$_2$ group.
shape changed from sharp to blunt in endothelial cells. Moreover, after treatment with colchicine, endothelial cells containing cholesterol crystals can hardly be seen using TEM in all visual fields, especially at the concentration of 10 nM. This phenomenon indicates that colchicine could inhibit the phagocytosis of cholesterol crystals and even dissolve cholesterol crystals, which may contribute to the improvement of the stability of atherosclerotic plaques.

Duewell et al. provided the first evidence that in the early stage of atherosclerosis, small cholesterol crystals were abundant and simultaneously accompanied by the infiltration of inflammatory cells, which could activate NLRP3 inflammasome and promote the activation of caspase-1 and the release of mature IL-1β [26]. Subsequent studies have found that activation of inflammasome could not only induce secondary inflammatory responses but also result in pyroptotic cell death [11]. Pyroptosis is a recently discovered form of programmed cell death that involves the initiation and progression of atherosclerosis [27]. In agreement with the previous study, our experiments in human umbilical vein endothelial cells demonstrated that exogenous cholesterol crystal stimulation could lead to pyroptotic cell death. Using TEM, numerous pyroptotic cells were observed in all fields.

**Figure 5:** Colchicine reverses the downregulation of various antioxidant enzymes and promotes the activation of AMPK-SIRT1 signaling in endothelial cells. HUVECs were treated for 24 h with different doses of colchicine (0–10 nM) in the presence of cholesterol crystal (0.5 mg/ml) or were left untreated (control). (a) Western blotting was dedicated to examine the protein expression levels of SIRT1, p-AMPKα, AMPKα, HO-1, SOD-2, and SOD-1. (b–f) Quantitative analysis of AMPK/SIRT1 pathway-associated protein expression. Data was expressed as the mean ± SD of three separate experiments. *P < 0.05, **P < 0.01 vs. the control group. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. the cholesterol crystal group.
Figure 6: Silencing of AMPK-SIRT1 signaling eliminates the protective effect of colchicine on endothelial cells. HUVECs were transfected with siRNA targeting AMPα1 (si-AMPKα1) and SIRT1 (si-SIRT1) or a control siRNA (Si NC) or were not transfected (-). Cells were then added to cholesterol crystal (0.5 mg/ml) in the presence of colchicine (10 nM) for 10 or 24 hrs. Real-time PCR analysis of the mRNA expression of AMPKα and SIRT1 after transfection with si-AMPKα1, si-SIRT1, and si-NC for 24 hrs without (a) or with (b) the presence of cholesterol crystals and colchicine. (c) Intracellular ROS level was detected using a DCFH-DA probe, and (d) mitochondrial membrane potential was tested by JC-1. (e) Pyroptotic cell death was measured with Hoechst 33342 (blue)/PI (red) double-fluorescent staining. (f, g) The indicators of oxidative stress GSSG and MDA were tested by assay kits. (h) Real-time PCR analysis of the mRNA levels of GSDMD and proinflammatory cytokines (IL-18, IL-1β, IL-6, IL-8, and MCP-1). Scale bars = 100 μm. Data was expressed as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. the si-NC group or CC+COL+si-NC group.
Figure 7: Continued.
pyroptosis-related proteins and the release of LDH were elevated significantly; on the contrary, the cell viability was obviously decreased. A study on gout shows that colchicine treatment significantly reduced MSU crystal-induced secretion of inflammatory cytokines (IL-1β and CXCL1) from macrophages and promoted macrophage differentiation into the anti-inflammatory M2 phenotype [15]. Since cholesterol crystals have the same physical and chemical properties with MSU crystals, both could activate NLRP3 inflammasome to abduct inflammatory response, which plays a causative role in inflammatory diseases. The previous study discovered that colchicine attenuated nonsteroidal anti-inflammatory drug-induced small intestinal injury by inhibiting the NLRP3 inflammasome activation [28]. Our in vitro results demonstrated that at the presence of colchicine, the pyroptotic cells were barely visible by TEM, along with decreased PI uptake, LDH release, and elevated cell viability. Meanwhile, the expression of NLRP3, ASC-1, and cleaved caspase-1 as well as the secretion of various inflammatory cytokines (IL-18, IL-1β, IL-6, IL-8, and MCP-1) was attenuated to varying degrees; the GSDMD N-terminal fragment was also reduced, especially at the concentration of 10 nM. These findings indicate that colchicine might be literally effective in suppressing the progress of atherosclerosis through inhibiting cholesterol crystal-induced endothelial cell pyroptosis.

Oxidative stress has direct damage to vascular parietal cells and is considered as a crucial driver in early atherogenesis [29]. The excessive accumulation of ROS, especially in mitochondria, plays an essential role in the occurrence of programmed cell death [30]. Previous studies highlighted that ROS is a vital upstream and positive regulator mediator in the activation of NLRP3 inflammasome [8, 31]. In our study, DCFH-DA probe detection shows that the stimulation of cholesterol crystals could induce ROS overproduction, along with the decrease of mitochondrial membrane potential, which was the same as 

\[
\text{H}_2\text{O}_2.
\]

As major indicators of oxidative stress, GSSG and MDA levels were also significantly improved. Nonetheless, this consequence could be eliminated by NAC, a ROS scavenger, and colchicine had an equivalent effect. Moreover, NAC and colchicine pretreatment significantly reduced the elevated proportion of PI-positive cells and LDH release induced by cholesterol crystals; in addition, the expression of NLRP3-related proteins and inflammatory factors was also remarkably suppressed.

**Figure 7:** Silencing of AMPK-SIRT1 signaling eliminates the protective effect of colchicine on endothelial cells. HUVECs were transfected with siRNA targeting AMPKα1 (si-AMPKα1) and SIRT1 (si-SIRT1) or a control siRNA (si-NC) or were not transfected (-). Cells were then added to cholesterol crystal (0.5 mg/ml) in the presence of colchicine (10 nM) for 24 hrs. (a) Western blotting was dedicated to examine the protein expression levels of SIRT1, p-AMPKα, AMPKα, HO-1, SOD-2, SOD-1, NLRP3, ASC-1, procaspase-1, and caspase-1 in endothelial cells. (b–i) Quantitative analysis of pyroptosis-associated protein and AMPK/SIRT1 pathway-associated protein expression. Values were expressed as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. the CC+COL+si-NC group.
which shows a powerful protective effect on endothelial cells. These results suggest that colchicine might repress pyroptotic cell death and NLRP3 inflammasome activation through inhibiting the generation of ROS induced by cholesterol crystals. This is also the first time that colchicine is confirmed to be effective in antioxidative stress and antipyroptosis beyond simple inflammation, indicating that colchicine has formidable potential in the cardioprotective role.

AMPK is a vital regulator of energy metabolism. In the prevention and treatment of AS, AMPK plays an important role in promoting cholesterol efflux, accelerating fatty acid oxidation and inhibiting inflammation [32–34]. Our results showed that colchicine treatment significantly increased the expression of phosphorylated AMPK and the downstream protein SIRT1. After silencing AMPKα, the expression levels of AMPK, p-AMPK, and SIRT1 were dramatically decreased. Whereas silencing of SIRT1 did not alter the expression of AMPK and p-AMPK, only the SIRT1 expression was downregulated significantly. These results confirmed that AMPK may be a pivotal upstream regulator of SIRT1. It has been shown that the activation of the AMPK/SIRT1 pathway could suppress the evolution of atherosclerosis by inhibiting endothelial cell oxidative stress and apoptosis, playing an effective and protective role in a variety of inflammatory-related disease [23, 35]. Our study also verified that colchicine could upregulate the expression of various antioxidant enzymes such as SOD-1, SOD-2, and HO-1 and reduce the production of ROS and the levels of GSSG and MDA, while mitochondrial membrane potential was improved significantly. Nevertheless, silencing of AMPKα and SIRT1 amelio-

![Figure 8: A model diagram showing the possible mechanism of colchicine alleviating cholesterol crystal-induced endothelial cell pyroptosis through activating the AMPK/SIRT1 pathway.](image)

rated colchicine-induced antioxidant enzyme upregulation, lower expression of ROS, downregulation of NLRP3 inflammasome-related proteins, and proinflammatory cytokines, suggesting that the specific mechanism of colchicine inhibiting endothelial cell pyroptosis might be tightly associated with the activation of the AMPK/SIRT1 pathway, which provides a strong theoretical basis for colchicine to become a promising therapeutic drug of atherosclerosis.

It is well known that the AMPK/SIRT1 pathway could modulate the function of vascular endothelial cells in diverse ways, for instance, activating eNOS, PGC-1α, p53, Nrf2, and FoxO3 and inhibiting the activity of various inflammation-related proteins such as p38MAPK and NF-κB pathway. Endothelial nitric oxide synthase- (eNOS-) derived nitric oxide (NO) has the properties of antihypertension, antithrombosis, antiatherosclerosis, and antiobesity [36]. Recent studies have shown that western diet-induced obesity could decrease the expression and activation of AMPKα and SIRT1, intensified aortic oxidative stress, increased related inflammatory responses, and diminished eNOS phosphorylation/activation and NO production, leading to endothelial stiffness, aortic fibrosis, and remodeling [37]. Metformin and resveratrol are both recognized AMPK/SIRT1 activators. It was found that long-term intake of fructose in rats could contribute to dysregulation of adipocytokine expression in perivascular adipose tissue (PVAT) and the loss of endothelium-dependent vasodilation, whereas AICA riboside (AICAR) stimulation could restrain gene expression of proinflammatory adipocytokines, facilitate eNOS phosphorylation in the aorta, and restore the loss of endothelium-
dependent vasodilation via activating the AMPK/SIRT1 pathway. Meanwhile, oral administration of resveratrol and metformin could produce the same effect [38]. Our research also confirmed that the phosphorylation of eNOS was significantly influenced by the stimulation of cholesterol crystals in vitro, but pretreatment with colchicine could reverse this alteration and ameliorate endothelial dysfunction against inflammatory insult in an AMPK/SIRT1-interdependent manner (Figure S1). In addition, the AMPK/SIRT1 pathway can also exert anti-inflammatory, antioxidative stress, and antiapoptosis effects by upregulating the PGC-1α pathway. PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) is a transcription coactivator of plentiful genes involved in energy management and mitochondrial biogenesis. In the rat model of myocardial ischemia/reperfusion injury, Tiliain could improve mitochondrial energy metabolism through AMPK/SIRT1/PGC-1α signaling, attenuate oxidative stress, significantly decrease the level of ROS and MDA, markedly alleviate myocardial infarction, evidently enhance myocardial pathological morphology, and reduce myocardial ischemia/reperfusion injury [39]. However, whether colchicine could also exert antioxidative stress via activating the PGC-1α pathway remains unknown; we need more experiments to prove it.

5. Conclusions

In conclusion, our present study provides the first evidence that colchicine could suppress the uptake of cholesterol crystals, promote the dissolution of cholesterol crystals in the endothelial cell, and inhibit endothelial cell inflammation and pyroptosis induced by cholesterol crystals. These effects may be achieved via activating the AMPK/SIRT1 pathway and inhibiting ROS production and oxidative stress. Therefore, colchicine is expected to become a potential drug for the treatment of atherosclerosis. However, further studies are required to validate whether colchicine could inhibit endothelial cell pyroptosis, thereby stabilizing atherosclerotic plaques and decreasing cardiovascular adverse events by activating the AMPK/SIRT1 pathway in vivo. Furthermore, the mechanism of colchicine inhibiting the uptake of cholesterol crystals still needs further experiments to explore.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

The abstract of this article was presented as an electronic poster at the 30th Great Wall Conference.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Authors’ Contributions

Mengyue Yang and Hang Lv designed the study, performed experiments, and wrote the manuscript. Qi Liu and Lu Zhang designed the study and wrote the manuscript. Ruoxi Zhang and Xingtao Huang performed experiments. Xuedong Wang, Baihe Han, and Gang Wang analyzed data. Shenglong Hou and Bo Yu reviewed the manuscript. Jingbo Hou designed the study and worked on the final approval of the manuscript and financial support.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81970297 (to J.H.), 81900309 (to Q.L.), 81801803 (to X.H.), and 81671794 (to J.H.)), the China Postdoctoral Science Foundation (2019M661306 (to Q.L.), 2018M641870 (to R.Z.), and 2018M640310 (to X.H.)), the Heilongjiang Postdoctoral Foundation (LBH-Z18217 (to Q.L.), LBH-Z19032 (to X.H.), and LBH-Z18141 (to R.Z.)), the Clinical special project of innovation science fund of Harbin Medical University (2018-KYYWF-0506 (to R.Z.)), the open project of the Key Laboratory of Myocardial Ischemia of the Chinese Ministry of Education (KF201914 (to S.H.) and KF201818 (to L.Z.)), and the Graduate Research and Practice Innovation Project of Harbin Medical University (YJSSJZX2019-35HYD (to M.Y.)).

Supplementary Materials

Figure S1: colchicine reverses the downregulation of eNOS phosphorylation by CC. HUVECs were treated for 24 h with different doses of colchicine (0–10 nM) in the presence of cholesterol crystal (0.5 mg/ml) or were left untreated (control). (a) Western blotting was dedicated to examine the protein expression levels of p-eNOS and eNOS. (b) Quantitative analysis of eNOS pathway-associated protein expression. HUVECs were transfected with siRNA targeting AMPKα1 (si-AMPKα1) and SIRT1 (si-SIRT1) or a control siRNA (si-NC) or were not transfected (-). Cells were then added to cholesterol crystal (0.5 mg/ml) in the presence of colchicine (10 nM) for 24 hrs. (c) Western blotting was dedicated to examine the protein expression levels of p-eNOS and eNOS. (d) Quantitative analysis of eNOS pathway-associated protein expression. Data was expressed as the mean ± SD of three separate experiments. *P < 0.05, ***P < 0.001 vs. the control group or CC+COL+si-NC group. ***P < 0.001 vs. the cholesterol crystal group (Supplementary materials)

References

[1] A. Janoudi, F. E. Shamoun, J. K. Kalavakunta, and G. S. Abela, “Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque,” European Heart Journal, vol. 37, no. 25, pp. 1959–1967, 2016.
[2] G. S. Abela, “Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation,” Journal of Clinical Lipidology, vol. 4, no. 3, pp. 156–164, 2010.
[3] K. Fujiyoshi, Y. Minami, K. Ishida et al., “Incidence, factors, and clinical significance of cholesterol crystals in coronary
plaque: an optical coherence tomography study,” *Atherosclerosis*, vol. 283, pp. 79–89, 2019.

[4] M. Lankafi and V. M. Dixit, ”Inflamasomes and their roles in health and disease,” *Annual Review of Cell and Developmental Biology*, vol. 28, no. 1, pp. 137–161, 2012.

[5] J. Shi, Y. Zhao, K. Wang et al., ”Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death,” *Nature*, vol. 526, no. 7575, pp. 660–665, 2015.

[6] S. Koka, M. Xia, Y. Chen et al., ”Endothelial NLRP3 inflamma-



ROS production?,” *Nature Reviews. Immunology*, vol. 10, no. 3, pp. 210–215, 2010.

[21] M.-I. Chen, L. Yi, X. Jin et al., ”Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway,” *Autophagy*, vol. 9, no. 12, pp. 2033–2045, 2014.

[22] T.-P. Shentu, M. He, X. Sun et al., ”AMP-activated protein kinase and Sirtuin 1 coregulation of cortactin contributes to endothelial function,” *Arteriosclerosis, Thrombosis, and Vascu-



[23] S. H. Chan, C. H. Hung, J. Y. Shih et al., ”Exercise intervention attenuates hyperhomocysteinemia-induced aortic endothelial oxidative injury by regulating SIRT1 through mitigating NADPH oxidase/LOX-1 signaling,” *Redox Biology*, vol. 14, pp. 116–125, 2018.

[24] X. Zhao, Y. Jin, L. Li et al., ”MicroRNA-128-3p aggravates doxorubicin-induced liver injury by promoting oxidative stress via targeting Sirtuin-1,” *Pharmacological Research*, vol. 146, p. 104276, 2019.

[25] G. S. Abela, A. Vedre, A. Janoudi, R. Huang, S. Durga, and U. Tamhane, ”Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization,” *The American Journal of Cardiology*, vol. 107, no. 12, pp. 1710–1717, 2011.

[26] P. Duewell, H. Kono, K. J. Rayner et al., ”NLRP3 inflamma-



[29] U. Forstermann, N. Xia, and H. Li, ”Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis,” *Circulation Research*, vol. 120, no. 4, pp. 713–735, 2017.

[30] K. Schroder and J. Tschopp, ”The inflamasomes,” *Cell*, vol. 140, no. 6, pp. 821–832, 2010.

[31] Y. Zhao, Z. Wang, D. Feng et al., ”p66Shc contributes to liver fibrosis through the regulation of mitochondrial reactive oxygen species,” *Theranostics*, vol. 9, no. 5, pp. 1510–1522, 2019.

[32] Y. Li, S. Xu, M. Mihaylova et al., ”AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice,” *Cell Metabolism*, vol. 13, no. 4, pp. 376–388, 2011.

[33] S. B. Vasamsetti, S. Karnewar, A. K. Kanugula, A. R. Thatipalli, J. M. Kumar, and S. Kotamraju, ”Metformin inhibits monocyteto-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis,” *Diabetes*, vol. 64, no. 6, pp. 2028–2041, 2015.

[34] Q. Yang, J. Xu, Q. Ma et al., ”PRKAA1/AMPKα1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis,” *Nature Communications*, vol. 9, no. 1. p. 4667, 2018.

[35] C. C. Thornton, F. Al-Rashed, D. Calay et al., ”Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation,” *Annals of the Rheumatic Diseases*, vol. 75, no. 2, pp. 439–448, 2016.
[36] N. Xia, U. Förstermann, and H. Li, “Resveratrol and Endothelial Nitric Oxide,” *Molecules*, vol. 19, no. 10, pp. 16102–16121, 2014.

[37] J. R. Sowers, J. Habibi, A. R. Aroor et al., “Epithelial sodium channels in endothelial cells mediate diet-induced endothelium stiffness and impaired vascular relaxation in obese female mice,” *Metabolism*, vol. 99, pp. 57–66, 2019.

[38] Y. Sun, J. Li, N. Xiao et al., “Pharmacological activation of AMPK ameliorates perivascular adipose/endothelial dysfunction in a manner interdependent on AMPK and SIRT1,” *Pharmacological Research*, vol. 89, pp. 19–28, 2014.

[39] L. Tian, W. Cao, R. Yue et al., “Pretreatment with Tilianin improves mitochondrial energy metabolism and oxidative stress in rats with myocardial ischemia/reperfusion injury via AMPK/SIRT1/PGC-1 alpha signaling pathway,” *Journal of Pharmacological Sciences*, vol. 139, no. 4, pp. 352–360, 2019.